Good MorningEquities moved higher on Wednesday despite a hot reading of the CPI. The CPI came in at 0.5% for the month or up a tenth hotter than expected with similar strength at the core and YOY levels. The takeaway is that inflation continues to rise and is leaving the FOMC no choice but to raise rates. Based on Jerome Powell’s testimony to Congress it looks like the Fed will be raising rates at a much quicker pace than ever indicated. According to the CME’s FedWath Tool, a rate hike is all but assured at the March FOMC meeting.
Today’s action will be driven by the PPI. The Producer Price Index is expected to subside from the previous month but could easily come in hotter than expected. Even so, with CPI already at record levels, a cool read on the PPI will do little to alter the outlook. The question is how will the market react?
Featured: Altucher: Trump’s Great Gain is starting (Ad) 
|
Markets | | | MarketBeat uses the latest technology to provide proprietary, comprehensive, accurate, and up-to-the-minute financial data. And because this information can be overwhelming, MarketBeat provides investors with the ability to input their stocks of interest (either those that are in their portfolio or on their watchlist) Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Stocks | | | Whether you are just getting started on your investing journey or you are an experienced trader looking to load up heavy on stocks priced at reasonable levels, focusing on stocks under $100 per share can really help you make the most out of every dollar you put to work. Read the Full Story |
|
Politics | | | Wall Street capped a day of wobbly trading with modest gains for stocks Wednesday, as investors weighed the implications of the latest economic snapshot showing rising inflation.
The S&P 500 rose 0.3% after veering between a loss of 0.1% and a gain of 0.8% over the course of the d... Read the Full Story |
|
From Our Partners | | Axcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream.
Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in. | | Click here to get the free alerts and see what’s coming next. |
|
Politics | | | Shares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker’s new Alzheimer’s disease treatment.
The Centers for Medicare and Medicaid Services said Tuesday after markets closed that patients taking Biogen’s Aduhelm will have to also ... Read the Full Story |
|
Politics | | | Stocks rose in morning trading on Wall Street Wednesday after the latest report of surging prices appeared to keep the Federal Reserve on track to raise interest rates later this year.
The S&P 500 rose 0.7% as of 10:18 a.m. Eastern. The Dow Jones Industrial Average rose 155 points... Read the Full Story |
|
|
Politics | | | At first, it didn’t even register as a threat. Then it seemed like a temporary annoyance.
Now, inflation is flashing red for the Federal Reserve's policymakers — and delivering sticker shock to Americans at the used car lot, the supermarket, the gas station, the rental office.
... Read the Full Story |
|
Politics | | | A severely corroded pipeline ruptured and spilled more than 300,000 gallons (1.1 million liters) of diesel fuel just outside New Orleans after the operator delayed needed repairs, according to federal records.
Most of the fuel drained into two artificial ponds called “borrow pits" and... Read the Full Story |
|
Markets | | |
Energy drink maker Monster Beverage (NASDAQ: MNST) shares have been rallying despite the market sell-off on merger speculation. The rising costs of aluminum, shipping costs and supply chain disruptions hurt margins resulting in a miss on in its Q3 2021 earnings report. While the Company doesn&rsqu... Read the Full Story |
|
Markets | | | There's no secret that real estate was a dizzying rollercoaster in 2021. If you didn't dip into real estate investing last year, here's a quick summary of what happened:
The pandemic completely bent the home-buying process last year. What to do about real estate in 2022? Here are some options. Read the Full Story |
|
Markets | | | After falling more than 31% from the all-time high set in late 2021 shares of Lululemon Athletica (NASDAQ: LULU) are ready to rebound. The market caved in the wake of the updated Q4 guidance and may move lower but we don’t think so. The market caved but on the charts, it looks like capitulation and capitulation is an opportunity for investors looking to ride the next rally. Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. | | View Today's Stock Pick |
|
